Fractyl Health Inc. logo

Fractyl Health Inc. (GUTS)

Market Closed
1 Sep, 20:00
NASDAQ (NMS) NASDAQ (NMS)
$
0. 71
-0
-0.3938%
$
104.55M Market Cap
- P/E Ratio
- Div Yield
6.96M Volume
- Eps
$ 0.71
Previous Close
Add Transaction
Day Range
0.69 0.77
Year Range
0.38 2.44
Want to track GUTS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Fractyl Health, Inc. - Special Call

Fractyl Health, Inc. - Special Call

Fractyl Health, Inc. - Special Call Company Participants Brian Luque Harith Rajagopalan - Co-Founder, CEO & Director Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Whitney Ijem - Canaccord Genuity Corp., Research Division Jason Gerberry - BofA Securities, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division William Wood - B.

Seekingalpha | 11 months ago
Fractyl Health says experimental procedure helps maintain weight-loss in study

Fractyl Health says experimental procedure helps maintain weight-loss in study

Fractyl Health said its experimental outpatient procedure helped preserve weight loss after discontinuation of a GLP-1 drug, sending the company's shares 23% higher in premarket trading on Friday.

Reuters | 11 months ago
Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Fractyl Health, Inc. (NASDAQ:GUTS ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Brian Luque - Corporate Participant Harith Rajagopalan - Co-Founder, CEO & Director Lisa A. Davidson - CFO & Treasurer Conference Call Participants Jason Matthew Gerberry - BofA Securities, Research Division Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Whitney Glad Ijem - Canaccord Genuity Corp., Research Division William McKinnie Wood - B.

Seekingalpha | 1 year ago
Fractyl Health: Speculative Buy With Binary Risk

Fractyl Health: Speculative Buy With Binary Risk

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected in Q3 2025. Current valuation reflects financing and trial risks, but may underappreciate Revita's clinical potential as a durable alternative to GLP-1 drugs. The company's cash runway is critically short, making the REMAIN-1 midpoint data a financial survival catalyst for raising capital on favorable terms.

Seekingalpha | 1 year ago
Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

Fractyl Health, Inc. (NASDAQ:GUTS ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Brian Luque - Head of Investor Relations and Corporate Development Harith Rajagopalan - Co Founder and Chief Executive Officer Lisa Davidson - Chief Financial Officer and Treasurer Conference Call Participants Avi Novick - Morgan Stanley Michael DiFiore - Evercore ISI Whitney Ijem - Canaccord Genuity Operator Good afternoon. And welcome to Fractyl Health's First Quarter 2025 Financial Results and Business Updates Call.

Seekingalpha | 1 year ago
Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Fractyl Health, Inc. (NASDAQ:GUTS ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Brian Luque – Head of Investor Relations and Corporate Development Harith Rajagopalan – Chief Executive Officer Lisa Davidson – Chief Financial Officer Conference Call Participants Mike Ulz – Morgan Stanley Michael DiFiore – Evercore ISI William Wood – B. Riley Securities Operator Good afternoon, and welcome to Fractyl Health's Fourth Quarter and Full Year 2024 Financial Results and Business Updates Call.

Seekingalpha | 1 year ago
After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS)

After Plunging -19.55% in 4 Weeks, Here's Why the Trend Might Reverse for Fractyl Health, Inc. (GUTS)

Fractyl Health, Inc. (GUTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks | 1 year ago
Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Fractyl Health, Inc. (NASDAQ:GUTS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-Founder and CEO Lisa Davidson - CFO Conference Call Participants Michael Ulz - Morgan Stanley Michael DiFiore - Evercore ISI William Wood - B. Riley Securities Operator Good afternoon, and welcome to Fractyl Health's Third Quarter Financial Results and Business Updates Call.

Seekingalpha | 1 year ago
Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

Fractyl Health, Inc. (NASDAQ:GUTS ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Stephen Jasper - Gilmartin Group Harith Rajagopalan - Co-founder and CEO Lisa Davidson - CFO Conference Call Participants Michael Ulz - Morgan Stanley Umer Raffat - Evercore Operator Good afternoon, and welcome to Fractyl Health's Second Quarter Financial Results and Business Updates Call. As a reminder, this conference call is being recorded.

Seekingalpha | 2 years ago